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De novo and inherited mutations in the X-linked gene CLCN4
are associated with syndromic intellectual disability and
behavior and seizure disorders in males and females
EE Palmer1,2, T Stuhlmann3,4, S Weinert3,4, E Haan5,6, H Van Esch7, M Holvoet7, J Boyle1, M Lefﬂer1, M Raynaud8,9,10, C Moraine8,9,10,
H van Bokhoven11, T Kleefstra11, K Kahrizi12, H Najmabadi12, H-H Ropers13, MR Delgado14,15, D Sirsi14, S Golla14, A Sommer16,
MP Pietryga16, WK Chung17, J Wynn17, L Rohena18, E Bernardo18, D Hamlin18, BM Faux18, DK Grange19, L Manwaring19, J Tolmie20,
S Joss20, DDD Study21, JM Cobben22, FAM Duijkers23, JM Goehringer24, TD Challman24, F Hennig25, U Fischer25, A Grimme25,
V Suckow25, L Musante13, J Nicholl26, M Shaw5,27, SP Lodh2, Z Niu28, JA Rosenfeld28, P Stankiewicz28, TJ Jentsch3,4, J Gecz5,27,
M Field1 and VM Kalscheuer13,25
Variants in CLCN4, which encodes the chloride/hydrogen ion exchanger CIC-4 prominently expressed in brain, were recently
described to cause X-linked intellectual disability and epilepsy. We present detailed phenotypic information on 52 individuals from
16 families with CLCN4-related disorder: 5 affected females and 2 affected males with a de novo variant in CLCN4 (6 individuals
previously unreported) and 27 affected males, 3 affected females and 15 asymptomatic female carriers from 9 families with
inherited CLCN4 variants (4 families previously unreported). Intellectual disability ranged from borderline to profound. Behavioral
and psychiatric disorders were common in both child- and adulthood, and included autistic features, mood disorders, obsessive–
compulsive behaviors and hetero- and autoaggression. Epilepsy was common, with severity ranging from epileptic encephalopathy
to well-controlled seizures. Several affected individuals showed white matter changes on cerebral neuroimaging and progressive
neurological symptoms, including movement disorders and spasticity. Heterozygous females can be as severely affected as males.
The variability of symptoms in females is not correlated with the X inactivation pattern studied in their blood. The mutation
spectrum includes frameshift, missense and splice site variants and one single-exon deletion. All missense variants were predicted
to affect CLCN4’s function based on in silico tools and either segregated with the phenotype in the family or were de novo.
Pathogenicity of all previously unreported missense variants was further supported by electrophysiological studies in Xenopus laevis
oocytes. We compare CLCN4-related disorder with conditions related to dysfunction of other members of the CLC family.
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INTRODUCTION
Chloride is the most abundant anion in vivo and is actively
transported and its level tightly regulated in virtually all
animal cells.1 Mammals express nine chloride channel (CLC) genes,
ﬁve of which encode 2Cl−/H+ exchangers (CIC-3-7) and four
Cl− channels (CIC-1,-2,-Ka,-Kb).2 The mainly endosomal/lysosomal
2Cl−/H+ exchangers may provide an electric shunt to facilitate
vesicular acidiﬁcation and accumulate vesicular chloride. In
contrast, CLC Cl− channels mainly reside in the plasma membrane

and are involved in the regulation of electrical excitability or
control extra- and intracellular ion homeostasis.2 The physiological
relevance of all members of the CLC gene family is highlighted by
mutations in various human diseases and mouse models, with
phenotypes including leukodystrophy, lysosomal storage disease,
severe neurodegeneration, myotonia, deafness, male infertility,
impaired renal function and osteopetrosis.2
Inherited single-nucleotide variants in CLCN4 (MIM *302910),
which encodes the 2Cl−/H+ exchanger CIC-4,3,4 were recently
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identiﬁed in ﬁve families with variable X-linked intellectual disability
(ID) and seizure disorder,5 one de novo variant was identiﬁed in a
male with epileptic encephalopathy6 and one de novo variant was
reported in a female with borderline ID and congenital diaphragmatic hernia.7 In humans, CIC-4 is widely expressed across tissues
with particularly high expression in the brain.8 ClC-4 resides predominantly on intracellular vesicles, but remains in the endoplasmic
reticulum, with a minor portion reaching the plasma membrane
when overexpressed heterologously.9 Its physiological function is
unclear, but CIC-4 is likely to be involved in the ion homeostasis of
endosomes and intracellular trafﬁcking.2 A role for CIC-4 in neuronal
differentiation has been suggested based on studies using primary
hippocampal neurons from Clcn4− / − mice and wild-type neurons
subjected to short hairpin RNA-mediated Clcn4 knockdown, which
showed a modest reduction in the total number of dendritic
branches per neuron.5 However, the pathophysiology of CLCN4related disorder in humans is not yet understood.
We report 10 additional families with nine novel CLCN4 variants,
extend the molecular spectrum to include splice site variants and
single-exon deletions, suggest genotype–phenotype correlation,
and present detailed clinical phenotypic information about CLCN4related disorder in 29 hemizygous males and 23 heterozygous
females from 16 families. Pathogenicity of previously unreported
missense variants is supported by electrophysiological studies in
Xenopus laevis oocytes.
MATERIALS AND METHODS
Families A, C, D, E and F were part of an X-chromosome exome resequencing
project reported by Hu et al.,5 with limited clinical information provided.
Family A was originally described by Claes et al.,10 as MRX49 (MIM: 300114)
(Figure 1); all available affected individuals (A:III:6, A:IV:2 and A:IV:4) were
reviewed by HVE (aged 52, 27 and 33) in 2015. Family C was originally
described by Raynaud et al.,11 as MRX15 (MIM: 300115) (Figure 1) and was
unavailable for review in 2016. The variant for the proband in family K was
reported by Yu et al.,7 as part of a case series of patients with congenital
diaphragmatic hernia but detailed clinical information was not provided. Ten
families (B, G–J and L–P) are previously unreported. Genetic studies were
approved by local ethics committees. Written informed consent was obtained
for molecular genetic analysis and the publication of clinical and radiological
data and photographs from all participants or their legal guardians.
Probands from families A, C-F, G, I and K-P had next-generation
sequencing (X-exome or whole-exome sequencing: details of laboratories
and methodologies are given in Supplementary Table 2);5,7,12-14 the proband
from family B was investigated by droplet-based multiplex PCR (7367
amplicons, 757 X-chromosome genes, 1.54 Mb),5,15 the proband from family
G had targeted sequencing of the coding exons of X-chromosomal genes as
part of a large-scale resequencing screen.16 Tested members of family J had
a clinical chromosomal microarray (v10.2 Baylor Miraca Genetics Laboratory,
Houston, TX, USA). The pathogenicity of missense variants was assessed
using in silico tools including combined annotation-dependent depletion
score17 and PolyPhen. Conﬁrmation of variants and segregation analysis was
conducted by Sanger sequencing using standard methods.
Analogous positions of amino acids mutated in CIC-4 were modeled in
the three-dimensional crystal structure of the algal CmClC, as previously
described.5 Missense variants were introduced into mammalian and oocyte
expression vectors by recombinant PCR in order to study their functional
effects. The subcellular localization of mutant CIC-4 proteins was investigated upon overexpression in COS-7 cells. CLCN4 variants were also
expressed in Xenopus laevis oocytes and their effect on the outward
rectifying CIC-4-mediated currents was measured as previously described.5

RESULTS
Pedigrees for families with inherited variants are provided in Figure 1,
with clinical information summarized in Table 1 and additional clinical
information for each family provided in Supplementary Table 1.
Global developmental delay and ID was reported for all males
(n = 29) and variable even within families, with severity varying from
borderline to severe. Expressive and receptive language was
commonly an area of particular concern. Ten (34%) males were
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reported to be of amiable personality with no signiﬁcant challenging behaviors or mental health concerns. Signiﬁcant behavioral or
mental health issues were noted in 19 (66%) males: heteroaggressive behavior was reported in 8 males, auto-aggressive
behavior in 3 males, repetitive autistic or obsessive–compulsive like
behaviors in 7 males and hyperactivity in 3 males. Depressive or
anxiety symptoms were reported in seven males (24%), including
two who had a diagnosis of bipolar disorder. A seizure disorder was
reported in 15 males (52%) from seven families varying from
infrequent seizures, well controlled with monotherapy (47%), to
severe infantile-onset intractable epilepsy (53%), even within a
family. Seizure types included infantile spasms, absence, myoclonic,
tonic, complex partial and generalized tonic-clonic. Three seizurerelated deaths were reported in family F, which may have resulted
from limited anti-epileptic treatment options. Reported EEG
ﬁndings included focal spikes, multifocal spikes and generalized
background slowing (data not shown). Infantile hypotonia was
common: reported in eight (27%) males across six families.
Additional neurological signs in childhood included strabismus
(3), cortical visual impairment (2), gait abnormality (1), upper limb
choreiform movements (1) and evolving upper limb/generalized
spasticity in childhood (2). Progressive ataxia and/or lower limb
spasticity were described after the third decade in four males from
two families (F and G). Abnormalities on neuroimaging/neuropathology were noted in seven males across ﬁve families (64% of
tested individuals, Figure 2). However, the majority of males did not
have neuroimaging and brain magnetic resonance imaging (MRI)
was normal in an additional four males. White matter abnormalities
and cortical atrophy were characteristic: periventricular leukomalacia and/or ventricular dilatation was noted in childhood in
three males with additional features of delayed myelination and
hypoplastic corpus callosum (for example, Figure 2:J1–6); one male
had cortical atrophy noted in his 20s and another male had marked
supra- and infra-tentorial atrophy and callosal thinning in his 60s
(Figure 2:F1–4). A hypoplastic corpus callosum was noted on
autopsy of a male who died aged 19 of a seizure-related death.
Although the previously reported adult members of families
A (MRX49)10 and C (MRX15)11 were considered to be non-dysmorphic, when reassessed with affected members of families B and F
(Figure 3) and D and G (TK and MF review), common dysmorphic
features in older male individuals included a long face with straight
nose and a prominent pointed chin that becomes more ‘squared off’
with age, and a relatively ﬂat midface. Facial features were not so
characteristic in younger males. Growth parameters were generally
within the normal range; however, many older individuals had a lean
body habitus; some males had macrocephaly (families A, F and P),
whereas microcephaly was noted in males from families B, I and O. No
consistent pattern of extra-neurocognitive symptoms was reported,
and many noted features are commonly seen in children with ID of
other causes: two affected infants had gastro-esophageal reﬂux and
aspiration/apnoeic events in early infancy, and feeding difﬁculties
were signiﬁcant for probands from families I and O. Three affected
males in family C had scoliosis and the affected male in family P had a
unilateral inguinal hernia, cryptorchidism and pes planus.
The phenotype in females (n = 18) from families with inherited
CLCN4 variants was strikingly variable, ranging from unaffected to
severely affected, even within a family (for example, family F). No
phenotype was recognized in tested/obligate heterozygous
females from families B, C, E, J and P. Two obligate female heterozygotes from family A were noted to have subtle learning/
behavioral difﬁculties. Three heterozygous females from family F
were asymptomatic, one had neuropsychiatric features and one
had severe ID with intractable seizure disorder, cerebral atrophy
and progressive spasticity and ataxia.
The phenotype in the ﬁve heterozygous females with de novo
variants was more severe and consistent with the phenotype in
hemizygous males. One had borderline, two had moderate and
two had severe-profound ID; again language development,
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Figure 1. Pedigrees of affected families A–G, J and P. Filled square = affected male; Filled circle = affected female; *Familial CLCN4 variant
present; wt, familial CLCN4 variant absent; NT, not tested. Note unaffected male IV:5 in family B has Klinefelter syndrome (47,XXY). Probands
from families H, I, K, L, M, N and O (pedigrees not shown) have de novo variants.
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Table 1.

Summary of phenotypic characteristics of male hemizygotes and female heterozygotes with CLCN4 variants

ID
Borderline
Mild
Moderate
Severe/profound
Seizure disorder
Well controlled
Intractable seizures
Behavioral issues/mental health disorders
Infantile hypotonia
Progressive neurological symptoms
Cortical atrophy, corpus callosum
hypoplasia or white matter hyperintensities
on neuroimaging

Affected males (n = 29)
Proportion of total cohort
(56%)

Heterozygous females with de novo
variants (n = 5)
Proportion of total cohort (10%)

Heterozygous females with inherited
variants (n = 18)
Proportion of total cohort (34%)

29/29 (100%)
1/29 (4%)
7/29 (24%)
9/29 (31%)
12/29 (41%)
15/29 (52%)
7/15 (47% of those
with seizures)
8/15 (53% of those
with seizures)
19/29 (66%)
8/29 (27%)
6/29 (21%)
7/11 (64% of tested)

5/5 (100%)
1/5 (20%)
0/5 (0%)
2/5 (40%)
2/5 (40%)
2/5 (40%)
1/ 2 (50% of those with
seizures)
1/ 2 (50% of those with
seizures)
3/5 (60%)
3/5 (60%)
1/5 (20%)
2/4 (50% of tested)

2/18 (11%)
0/2 (0%)
1/ 2 (50% of those with ID)
0/2 (0%)
1/ 2 (50% of those with ID)
1/18 (6%)
0/1 (0%)
1/1 (100% of those with
seizures)
3/18 (17%)
0/18 (0%)
2/18 (11%)
1/1 (100% of tested)

Abbreviation: ID, intellectual disability.

Figure 2. Neuroimaging of affected individuals with CLCN4-related condition at different ages. F1–4: CT images of individual F:IV:3, aged 66. Noncontrast multi-slice helical acquisitions, thick-slice reconstructions only. F1: sagittal midline image depicts callosal thinning, atrophic midbrain and
cerebellar atrophy with prominent quadri-cerebellar cistern. F2: axial image of posterior fossa depicting cerebellar vermian atrophy with
increased caliber of the adjacent CSF spaces. F3: axial image depicting prominent Sylvian ﬁssures and increased caliber of lateral and third
ventricles with surrounding atrophic change and evidence of a right frontal infarct. F4: coronal image showing disproportionate cerebellar
atrophy and prominence of the adjacent CSF spaces. J1–6: MRI images of individual J:III:2 aged 4 and 8. J1: Axial FLAIR image from individual J:
III:2, aged 4, depicting enlarged Sylvian ﬁssures secondary to surrounding volume loss, particularly affecting the frontal lobes. J2: coronal T2
weighted image from individual J:III:2 aged 4 depicting generalized white matter volume loss. J3 Axial FLAIR image from individual J:III:2 aged 8
demonstrating periventricular leukomalacia. J4: coronal FLAIR image from individual J:III:2 aged 8. Images depict that despite interval progression
of myelination between the ages of 4 and 8, there is still signiﬁcantly delayed myelination involving the anterior frontal, posterior parietal and
temporal lobes. The corpus callosum is normally formed but attenuated. There is pronounced global volume loss, preferentially affecting the
white matter. Prominent perivascular spaces are seen bilaterally. L1–3: MRI images from family L proband at four months of age. Diffuse cortical
hypoplasia with resultant prominence of the extra-axial CSF spaces and thinning of the corpus callosum without other morphologic
abnormalities. Myelination is otherwise grossly normal. N1–2 MRI images from proband from family N aged 10. N1: sagittal T1 weighted midline
image showing dilated third ventricle. N2: Coronal T2 weighted image showing dilated third ventricle. I1–2: images from proband from family I
aged 13 months. I1: sagittal T1 weighted midline image showing dilated lateral ventricles. I:2: axial T2 weighted image showing volume loss,
periventricular leukomalacia and dilated ventricles. CSF, cerebrospinal ﬂuid; MRI, magnetic resonance imaging.
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Figure 3. Facial features of affected individuals with CLCN4-related disorder in age order. In older males note the elongated face, straight nose
and pointed prominent chin that becomes relatively ‘squared off’ with age that is particularly prominent in affected adult males from families
A, B, C and F (F:IV:3), and mildly present in the 9-year-old F:V:1 and 12-year-old affected male from family P. A relatively ﬂat midface is
noticeable in several individuals (particularly A:III:6 and affected members of family C). Individuals F:IV:3 and F:IV:5 have relative ‘coarsening’ of
facial features with age; however, they were both treated with phenytoin, which can coarsen features and F:IV:5 had multiple facial injuries
secondary to epileptic drop attacks. Although the facial phenotype is less distinctive in younger children and females (family F:V:1 and F:V2 as
infants, and affected individuals from families O, I, L, H, N and M) some similarities include young children having relatively rounded faces and
affected females from families H, L and F (F:IV:5) having down-sloping palpebral ﬁssures and depressed nasal bridges. Clinical pictures from
family C were ﬁrst published in Raynaud et al.11 and reproduced from John Wiley & Sons with permission.
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especially expressive language, was an area of particular concern.
Two girls (40%) had seizure disorders of varying severity. Two girls had
self-injurious behaviors and one was assessed as emotionally reactive;
the other two girls had no signiﬁcant behavioral issues. Three girls
(60%) had infantile hypotonia and one developed mildly increased
peripheral tone with brisk patellar reﬂexes. Four girls had neuroimaging by MRI: reported as normal for two (both assessed below the age
of three). There was subtle neuropathology in the other two with
diffuse cortical and corpus callosum hypoplasia in one, and persistently enlarged third ventricles and T2/FLAIR subcortical hyperintensities in the other (Figure 2). Two of the ﬁve girls had signiﬁcant
feeding difﬁculties in infancy; one had congenital diaphragmatic
hernia and bilateral hip dysplasia, and one had scoliosis. Two of the
girls had microcephaly: other growth parameters were within normal
limits (Supplementary Table 1). Subtle dysmorphic features were noted
in three girls (Figure 3) including down-sloping palpebral ﬁssures with
depressed nasal bridge. We are also aware (JR) of another female (not
included in this study) with a novel de novo missense variant in CLCN4,
p.Ile195Phe, with a similar clinical phenotype including ID, infantile
hypotonia, autistic features, focal seizures, microcephaly and periventricular leukomalacia/hypomyelination on cerebral MRI.
X inactivation studies were performed for eight female heterozygotes. In an asymptomatic heterozygote from family F,
X inactivation was skewed (87%:13%); in all other females it was
random or non-informative (Supplementary Information). None of
the severely affected females had an alternative cause identiﬁed for
their clinical features when subjected to other genetic (including
chromosomal microarray) and metabolic testing, including wholegenome sequencing for the severely affected female in family F.
In addition to the one frameshift variant (p.Asp15Serfs*18,
family A) and four missense variants (p.Gly731Arg, p.Gly78Ser,
p.Leu221Val, p.Val536Met; families C-F) reported in Hu et al.5 and
the p.Asp15Asn in family K reported by Yu et al.,7 an additional
novel CLCN4 frameshift variant was identiﬁed in family B
(p.Ile626Asnfs*135), six novel missense CLCN4 variants were
detected in families G, H, I, L, M and N (p.Val212Gly, p.Leu221Pro,
p.Ser534Leu, p.Ala555Val, p.Arg718Trp and p.Val275Met), and a
novel intragenic microdeletion of exon 12 (hg19 chrX: g.
(10182428_10187807)_(10189796_10201480) del mat) predicted
to result in a frameshift and premature stop codon was detected
in family J (Supplementary Table 2, Figure 4, Supplementary
Figure 3). The proband in family O had the same p.Gly544Arg
missense variant (but a different nucleotide substitution) as the
affected individual with epileptic encephalopathy reported by
Veeramah et al.6 In proband O, this missense variant appeared to
be de novo but present in mosaic form (70% of the cells). The
proband and his unaffected mother in family P had a novel
intronic variant (IVS9+5G4A) predicted to affect splicing leading
to in-frame deletion of exon 9. Exon 9 would be predicted to be a
critical exon as it codes for four helical transmembrane domains.
To test the in silico prediction, for variant IVS9+5G4A, we
performed reverse transcriptase-PCR experiments on RNA extracted
from lymphoblastoid cell lines using CLCN4 primers located in exon
8 and exon 10. In the proband and his mother, two speciﬁc ampliﬁcation products were obtained, with the larger product corresponding to properly spliced wild-type CLCN4 transcripts with exon
9 spliced in and the smaller product corresponding to transcripts
with exon 9 skipped (Supplementary Figure 2). In contrast, a single
wild-type product was seen in controls (Supplementary Figure 2).
Skipping of exon 9 would result in mutant ClC-4 protein with 182
amino acids deleted, supportive of the in silico pathogenicity
prediction. The results also indicated that the mutated allele is not
X-inactivated in the unaffected mother’s blood lymphocytes.
The accession numbers for the novel sequences reported in this
paper are ClinVar: SCV000245780–SCV000245788, SCV000266304
and SCV000266305.
All missense variants were predicted to affect function by in
silico software analysis, were not listed in publicly available

databases including ExAC, affected highly evolutionary conserved
amino acids (Supplementary Figure 1) and either segregated with
the condition in the family (Figure 1) or were de novo, with no
other plausible genetic cause detected on exome sequencing and
chromosomal microarray (Supplementary Information).
We examined the position of the novel missense variants using
the RCSB protein bank (Figure 4a) and modeled the analogous
positions of amino acids mutated in CIC-4 in the three-dimensional
crystal structure of CmCLC, a Cl−/H+ antiporter from Cyanidioschyzon merolae18 (Figure 4b and Supplementary Table 2). The majority
of the missense variants affect residues in the transmembrane part
that contains the ion translocation pathway, often close to the
interface of the two subunits of the dimeric transporter. Two
variants are located, also close to the interface, in the cystathionineβ-synthase domains, which have a role in the voltage-dependent
activation of CLC channels19 and transporters.20 The previously
reported de novo missense variant in family K (p.Asp15Asn)7 is
located in the N-terminal cytoplasmic domain, which is not resolved
in the crystal (Supplementary Table 2). The exonic deletion present
in family J (Supplementary Figure 3A) did not overlap with any
predicted benign copy number variants in curated databases
(Database of Genomic Variation) and no overlapping variants were
present in the laboratory database. This array ﬁnding was
independently validated in a separate laboratory (Supplementary
Figure 3B). The intronic variant in family P was not listed in ExAC
and affects a highly conserved nucleotide (Supplementary Figure 1).
These genotypic ﬁndings are consistent with, and extend beyond
those of Hu et al.5 As previously shown for the ClC-4 variants reported
by Hu et al.5 and Veeramah et al.,6 we found that the novel variants p.
Val212Gly, p.Leu221Pro, p.Ser534Leu, p.Ala555Val, p.Arg718Trp and p.
Val275Met, reduced or abolished the strongly outwardly rectifying
CIC-4 currents (Figure 4c). In comparison, the previously reported
variant p.Asp15Asn7 in family K yielded wild-type like currents when
heterologously expressed (Figure 4c). Western blots of individual
oocytes showed equal CIC-4 protein expression levels for all mutants
(Supplementary Figure 4). Similar to overexpressed wild-type ClC-4
and the previously reported CLCN4 missense variants,5,6 all examined
missense variants localized predominantly to the endoplasmic reticulum when overexpressed in COS-7 cells (Supplementary Figure 5).
However, as native CIC-4 may localize to endosomal compartments,21
this does not exclude a trafﬁcking defect in vivo.
DISCUSSION
This case series indicates that the CLCN4-related condition should
be considered a syndromic form of X-chromosome-linked ID,
behavioral disorder and epilepsy with complete penetrance but
variable expressivity in males, and incomplete penetrance and
variable expressivity in females.
Although a larger case series will be required to precisely deﬁne
phenotype–genotype correlations and for this we are curating a
publically accessible CLCN4 website, as part of the Human Disease
Genes Website Series, some initial observations can be made. Most
variants are missense rather than protein truncating. Three
mutations are likely to result in a complete loss of ClC-4 function
in hemizygous males; these are frameshift variants in exons 3 and
11 (families A and B) and deletion of exon 12 (family J). Phenotypes
of males and females with frameshifts or exonic deletion are relatively mild compared with the majority of affected individuals with
missense variants (Supplementary Table 1), which may suggest that
an abnormally functioning CIC-4 antiporter is more deleterious than
a reduction in its levels or a complete absence. It is tempting to
speculate that this stronger effect of missense variants may be
mediated by a heteromerization of the mutated ClC-4 protein with
homologous CLC proteins.22 However, no potential dominantnegative effect of CLCN4 missense variants was observed when
equal amounts of wild-type and mutant ClC-4 were expressed
in Xenopus oocytes. The corresponding currents could not be
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Figure 4. Genotypic information, three-dimensional modeling and functional studies of CLCN4 variants. (a) Position of CLCN4 variants in
families A–P (information adapted from Protein Data Bank P51793). Missense variants in families D (p.Gly78Ser), G (p.Val212Gly),
L (p.Ala555Val) and O (p.Gly544Arg) are within helical transmembrane domains of the protein. Missense variants in families F (p.Val536Met),
I (p.Ser534Leu) and N (p.Val275Met) are within helical-intramembrane domains. Missense variants in families E (p.Leu221Val) and H (p.
Leu221Pro) lie within a loop between transmembrane domains. Missense variants in families C (p.Gly731Arg) and M (p.Arg718Trp) lie within
the second cytosolic cystathionine-β-synthase (CBS) domain and therefore may affect gating. (b) Analogous positions of amino acids mutated
in ClC-4 highlighted in the crystal structure of CmClC. Amino acids are displayed as spheres in colors. CLC transporters are (homo)dimers of
identical subunits with two ion translocation pathways. Each subunit is composed of a transmembrane domain (TMD) containing several
intramembrane helices and cytosolic CBS domains. Asterisks indicate previously published analogous positions of amino acids.5,6 (c) Current
voltage relationships of the electrogenic 2Cl−/H+ exchanger ClC-4 and the CIC-4 variants expressed in Xenopus oocytes, shown as mean values
of normalized steady-state currents from several oocytes (numbers indicated in ﬁgure, in parentheses: number of independent cRNA batches
injected). The current of wild-type (WT) CIC-4 is strongly outwardly rectifying, that is, increases steeply at inside-positive voltages. The human
missense mutations p.Val212Gly, p.Leu221Pro, p.Val275Met, p.Ser543Leu, p.Ala555Val and p.Arg718Trp reduced, or even abolished, these ClC-4
currents. Only variant p.Asp15Asn exhibited normal wild-type like currents. Error bars, s.e.m. Noninjected (n.i.) oocytes served as control.
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distinguished from a superimposition of currents from WT and
mutant ClC-4 transporters (Supplementary Figure 6).
One variant is recurrent: the male in family O has the same
amino-acid change (p.Gly544Arg) as previously reported by
Veeramah et al.,6 although in mosaic form, and there are phenotypic
similarities with both affected males having severe developmental
delay/ID, a refractory seizure disorder and microcephaly. There are
two families (H and E) where the same amino acid is mutated but to
different amino acids. We compared the clinical phenotype and the
electrophysiological effect of these variants when heterologously
expressed. In family H, the heterozygous female with a de novo
alteration of leucine 221 to proline, is affected with moderate
developmental delay and hypotonia with no seizure disorder
(Supplementary Table 1). In family E, where leucine 221 is altered
to valine, affected males have a relatively mild phenotype
(mild–moderate ID and only one with a well-controlled seizure
disorder) and female heterozygotes are unaffected. The p.Leu221Pro
variant has a Grantham score of 98 as opposed to p.Leu221Val, which
has a Grantham score of 32.23 We recognize increasing caution in the
ion channel literature regarding the accuracy of in silico tools in
interpreting clinical severity. For example, although Brunklaus et al.24
found some correlations between predicted physico-chemical
differences (using Grantham scores) of 41300 variants in a range
of sodium ion channel genes and the clinical severity of the
corresponding cardiac, muscular or neurological disorder, they also
acknowledged the great variability in clinical expression among
members of the same mouse or human family, postulating the
importance of differences in genetic background between individuals.
Nevertheless, when heterologously expressed in Xenopus oocytes the
ClC-4 p.Leu221Pro variant identiﬁed in our study essentially abolished
the CIC-4 current (Figure 4c) as opposed to the Leu221Val variant,
which only resulted in modest reduction in CIC-4 current (Hu et al.5;
Figure 1b). Although these genotypic differences may contribute to
the differences in clinical phenotypes in females between families E
and H, more complex genetic reasons may be contributory. For
example, disparities may be attributed to differences in genomic
backgrounds and X inactivation patterns in the brain.
The striking phenotypic variability in females with CLCN4related disorder is similar to that seen in several other X-linked
conditions, such as female heterozygotes with mutations in PHF6
(ref. 25) (MIM:300414) and DDX3X (ref. 26) (MIM:300160). Although
CLCN4 is subject to X inactivation, blood DNA-based X inactivation
studies did not predict clinical outcome in heterozygous females.
This is perhaps not surprising as recent mouse studies27
demonstrate the complexity of X inactivation in different cells
and organs, so that X inactivation in peripheral blood cells may
not reﬂect X inactivation patterns in the same individual’s brain.
For both affected females and males from the families
investigated here, the phenotype is primarily neurocognitive. Only
one individual had additional congenital anomalies that is the
female in family K (p.Asp15Asn) with a congenital diaphragmatic
hernia.7 It is not clear that this anomaly was caused by the CLCN4
variant: for example, no other individuals with CDH described in Yu
et al.’s7 case series had variants in CLCN4 and there is no supportive
evidence from mouse models that CIC-4 is important in diaphragm
development.11 In addition, the pathogenicity of this cytoplasmic
variant remains uncertain; although it is de novo and affects an
amino acid conserved between species, electrophysiological
analysis of Asp15Asn expressing oocytes yielded wild-type currents
(Figure 4c). We have listed this variant as a variant of uncertain
signiﬁcance in ClinVar (accession number SCV000266305).
Additional longitudinal clinical data and serial neuroimaging, in
particular imaging that is more sensitive to subtle white matter
abnormalities, such as FLAIR images (MRI) and PET, will clarify how
common white matter changes, cortical atrophy and progressive
neurological symptoms are in CLCN4-related disorder, and whether
there is a causal association, or whether some of the changes could
be acquired. Progressive neurological/neuroanatomical features were

noted for individuals with and without a seizure disorder, suggesting
that these features were not due solely to uncontrolled seizures
causing excitotoxic damage, as has been suggested for other
conditions.28 Variable neurological features and leukodystrophy have
been described in humans and mice with variants in other members
of the CLC protein family.2 Autosomal recessive loss-of-function
variants in CLCN2 (MIM *600570) cause a leukoencephalopathy
associated with myelin vacuolation in the brain and spinal cord in
mice29 and humans.30 Patients with CLCN2 variants display variable
neurocognitive symptoms, including ataxia, mild spasticity, visual
ﬁeld defects and learning disabilities.30 Clcn3−/− mice display severe
progressive neurodegeneration.31 Clcn6−/− mice have moderate
behavioral abnormalities and a mild form of lysosomal storage
disease predominantly affecting neuronal axons.32 Neither gene is
currently associated with a recognised human phenotype. Lastly,
cerebral atrophy and learning difﬁculties have been described in
individuals affected by autosomal recessive CLCN7-related disorder
(MIM #611490) and knock-out mice display lysosomal storage/
neuronal ceroid lipofuscinosis features.33
More work is required to understand the pathophysiology of
CLCN4-related conditions in humans. Decrease in CIC-4 Cl−/H+exchange activity may impair the ion homeostasis of endosomes
and intracellular trafﬁcking.2 No obvious white matter changes or
neurodegeneration in the brains of Clcn4−/− mice were observed
when examined with luxol staining for myelin (Supplementary
Figure S7). However, moderate abnormalities in dendritic branching
were reported for cultured hippocampal neurons from Clcn4−/− mice
and for wild-type neurons subjected to short hairpin RNA-mediated
Clcn4 knockdown,5 changes reminiscent of those seen in other
neurodevelopmental conditions.34 The fact that Clcn4−/− mice do
not show a recognizable neurological or behavioral phenotype5,35
could reﬂect differences in the role of CIC-4 between species or in
compensating mechanisms between species. Moreover, Clcn4 is
autosomal (on chromosome 7) and has truncated introns in the
mouse species Mus musculus, whereas CLCN4 orthologues are on
the X-chromosome in other animals and mouse species such as
Mus spretus.36 Potentially this could have implications for differential
gene expression timing, regulation and subsequent function
between CLCN4 and Clcn4 in the humans and mouse. Indeed the
rat, where the CLCN4 orthologue is on the X-chromosome, may be
an attractive additional animal model for future research.
Currently, treatment for this condition is limited to early
intervention, special education, family support and treatment for
associated seizure, behavioral, sleep and mental health conditions.
The degree of ID was more severe in affected individual(s) from
families with a more severe seizure phenotype (for example,
families F and J), supporting the prioritization of aggressive seizure
control to optimize developmental outcome. No particular antiepileptic medication was found to be consistently more effective in
the eight families with seizure disorder, although three individuals
in families F and O had signiﬁcant improvement with the addition
of lamotrigine that inhibits voltage-sensitive sodium channels and
is thought to inhibit the pre-synaptic release of glutamate, which
may have an additional neuroprotective effect.37 Although no
currently used medication is known to speciﬁcally activate the CIC-4
transporter,38 better understanding of the underlying pathophysiology of CLCN4-related disorder may allow targeted treatment.
The growing number of clinical cases with variants that very likely
affect CLCN4’s function is striking, given how recently this condition
was ﬁrst described6 and conﬁrmed as a clinical condition.5 We
recommend that CLCN4 be included in panels for the investigation
of undiagnosed epilepsy and ID for both males and females.
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